AGC Biologics acquires commercial-scale facility from AstraZeneca

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Susan Vineyard)
(Image: Getty/Susan Vineyard)

Related tags: Astrazeneca, AGC Biologics, Colorado

The Colorado site currently possesses two 20,000L bioreactors, with the potential to add four more.

AGC Biologics, a contract development and manufacturing organization (CDMO), used the services of International Process Plants to find a pre-existing, US-based facility.

The CDMO will invest $100m (€89m) into the project, acquiring the facility from previous owners AstraZeneca, which had taken the decision to close the facility in the beginning of 2019​ to consolidate its manufacturing capabilities. Since that time, no production has been occurring at the idled plant.

The site, which AZ had originally bought from Amgen in 2015​, covers approximately 330,000-square-feet and is expected to begin commercial-scale operations by April 2021.

Currently, the facility contains two 20,000L stainless steel mammalian cell bioreactors but it has space for up to four additional bioreactors of the same size.

According AGC Biologics, the decision was taken to find a larger-scale facility due to a “higher ratio of late-phase and commercial projects”​ within its portfolio.

The fully operational site will contribute 280 jobs to Boulder, adding to the CDMO’s workforce of more than 1,000 employees across the US, Denmark, Germany, and Japan.

AGC Biologics’ CEO, Patricio Massera, stated that the purchase was part of a wider ‘expansion initiative’ to support customer demand for mammalian projects.

In 2018​, the company chose to begin work on a building complex in Bothell, US, as its new global headquarters, specifically in order to expand in the US.

Related news

Show more

Related products

show more

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 20-Jan-2020 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

Microaerobic Fermentation of Lactobacillus acidophilus

Microaerobic Fermentation of Lactobacillus acidophilus

Eppendorf for Bioprocess – Solutions that grow with you | 01-Oct-2019 | Application Note

We successfully performed microaerobic fermenta¬tion of a probiotic strain, Lactobacillus acidophilus, at a very low oxygen level, representing the natural...

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Related suppliers

Follow us

Products

View more

Webinars